I know the headline sounds like bad clickbait, but there’s an anti-obesity medication that’s disrupting the industry. According to a recent article from The New York Times, the drug is so effective that obese patients who take it could also prevent other consequences such as diabetes. The drug is semaglutide from Novo Nordisk, and it’s already marketed as a treatment for Type 2 diabetes.
Is This Drug the Future of Weight Loss?
A drug marketed for Type 2 diabetes could change the way we treat obesity in the future.
Feb 17, 2021
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
